REED JOHN C Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$24,999.00
Insider Sells Quantity
4
Insider Sells Sum
$221,724.50

Insider Activity of REED JOHN C

According to the SEC Form 4 filings, REED JOHN C, being in a position of

  1. EVP, Innovative Medicine, R&D at Johnson & Johnson,
    оver the last 12 months, has bought 0 shares, and sold 32210 shares for $7.83M,
    over all time since 2025-07-17, has bought 0 shares, and sold 73068 shares for $15.14M.

Biography of REED JOHN C

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $7,827,0301100

Comparison of Insiders on Amount of Buys and Sells

2026-02-17SaleJohnson & Johnson
JNJ
EVP, Innovative Medicine, R&D
32,210
0.0013%
$243.00$7.83M+3.04%
2025-10-17SaleJohnson & Johnson
JNJ
EVP, Innovative Medicine, R&D
21,721
0.0009%
$192.71$4.19M+24.64%
2025-07-17SaleJohnson & Johnson
JNJ
EVP, Innovative Medicine, R&D
19,137
0.0008%
$163.55$3.13M+35.73%
2012-09-06SaleIonis Pharmaceuticals, Inc.
IONS
director
4,900
0.0048%
$15.18$74,358+10.94%
2012-09-04SaleIonis Pharmaceuticals, Inc.
IONS
director
5,100
0.0017%
$5.17$26,367+11.46%
2012-07-09SaleIonis Pharmaceuticals, Inc.
IONS
director
10,000
0.0028%
$3.95$39,500+1.64%
2012-06-22SaleIonis Pharmaceuticals, Inc.
IONS
director
10,000
0.0068%
$8.15$81,500+17.75%
2008-10-02PurchaseRoyalty Pharma plc
RPRX
director
3,846
0.0002%
$6.50$24,999
Total: 8
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.